Parliament Workbench
Data: Official Report to 19 Nov 2026

Official Report · Committee

Continued Petitions

Thyroid and Adrenal Testing and Treatment (PE1463)

Thursday 15 June 2017 Public Petitions Committee About 09:15–10:00 Petitions 38 contributions · 8 speakers

Speakers

Choose an MSP to read only their contributions

The record

38 contributions
Johann Lamont Lab The Convener · Glasgow
link

The next continued petition is PE1463, by Sandra Whyte, Marian Dyer and Lorraine Cleaver, on effective thyroid and adrenal testing, diagnosis and treatment. We are joined by the lead petitioner, Lorraine Cleaver, and by Dr John Midgley. We are also joined by Elaine Smith, who has an interest in the petition. I welcome you all to the meeting.

Johann Lamont Lab The Convener · Glasgow
link

Ah well—we will get started.

We have a full agenda today so I ask members and witnesses to keep their comments succinct. Members will be aware that a lot of information from a range of stakeholders has been gathered on the petition since it was launched in 2012. We intend to have a focused discussion.

I will allow five minutes for Lorraine Cleaver or Dr Midgley to make an opening statement.

John Midgley
link

Good morning. I will start with a bit of history. Nearly 50 years ago, my wife was a technician in Newcastle University’s department of medicine during the time of Professor Reginald Hall, who was an authority on thyroid function, test development and diagnosis. She ran the test for thyroid stimulating hormone—the first to be developed in this country—and, after a while, she began to feel ill. The professor said that, as she was doing the tests, it was just suggestion. However, when she put her serum sample into a test run, lo and behold, her thyroid stimulating hormone level was up in the sky. She was suffering from Hashimoto’s thyroiditis, which ultimately destroyed her thyroid.

I was a lecturer in Newcastle University on an altogether different subject but, naturally, I became interested in the thyroid, how it worked and how it was treated. By a series of coincidences, I got into the position of being able to invent the thyroid function test for free thyroxine and free triiodothyronine that is now used worldwide.

In the 40 years since the late 1970s, I have taken an interest in the development of the testing, treatment and diagnosis of thyroid patients and I have become increasingly unhappy about the way in which testing has proceeded. It is unfortunate that the test for thyroid stimulating hormone that I mentioned is now overreaching. It is supposed to be successful in diagnosing the onset of disease through testing for thyroid underfunction or overfunction—for which it is perfectly suitable—as well as for the control of treatment, for which it is totally unsuitable. Extending its use to a function for which it is unsuitable has led to a significant number of patients being wrongly diagnosed, wrongly treated or not treated at all.

I have written down some general statements because, at my age, I sometimes lose my memory. I hope to convince you that the current paradigm of thyroid deficiency treatment is insufficient and is wasteful of medical time and resource, and that the wrong tests are being administered to control treatment. The approach commits the sin of categorisation. By that, I mean that the diagnosis and treatment are aimed at putting people into the normal range, which is a wide range, and individuals each have their own positions in it. Looking at all the people here today, it would be fair to say that there will be somebody who is very much different from the average, and it is not sufficient just to put someone in the range; you have got to put them in the range in the position where their optimum health is to be found. Since you do not know what that value was when they were well—because it was never measured—there is a lot of flailing about going on to find out what the best solution is. That is what I mean by the sin of categorisation. It is shoehorning people into the normal range and saying, “That’s okay—job done.” That is wrong.

The next problem is the promotion of biochemical markers for the measurement of thyroid hormones in blood over patient presentation. At the moment, the chemistry dominates the presentation of symptoms by the patient. That is the wrong way round. The presentation of symptoms by the patient should dominate over biochemical parameters, which should be suggestions and indicators but not dictators of the situation. That is very important.

All that has been to the detriment of the health, wellbeing and economic activity of mainly female patients, as 80 to 90 per cent of thyroid sufferers are female. We males are a little less aware of the situation than women are in that respect, because at least 2 per cent of women have thyroid problems, which is quite a significant number given the population.

In short, I believe that there should be an unbiased review of present protocols for treatment and diagnosis in the light of new evidence that shows that the single use of thyroid stimulating hormone as a test for thyroid deficiency and for treatment is unsuitable and misleading.

Johann Lamont Lab The Convener · Glasgow
link

Thank you very much.

As you will be aware, the Scottish Government agreed to conduct a listening exercise, and in doing so commissioned Thyroid UK to conduct a patient survey. You expressed disappointment with the manner in which the Scottish Government approached the listening exercise and with its response to the survey. Do you have a view on how the listening exercise could have been conducted differently, and do you have any suggestions in that regard?

John Midgley
link

Lorraine Cleaver may have some suggestions.

Lorraine Cleaver
link

My suggestion is the one that was mooted at the committee a few years ago, which is to have an inquiry run by the committee. The listening exercise was an exercise in wasting money, wasting time and achieving zero. I met with a Scottish Government minister shortly after the listening exercise was agreed on, and he discussed setting up a short in-house inquiry with medical people and patients suffering not only from thyroid disease but from fibromyalgia or ME, and running a long-term project over a year. Nothing happened with that. I know the budget that was set aside for that, but nothing came of it. The Thyroid UK survey was a very small part of the listening exercise; it was not the listening exercise itself. Nothing was done with the findings of the Thyroid UK survey; in fact, I think that they were roundly ignored by the minister who came here.

In more than four and a half years—indeed, almost five years—we have not achieved anything. We have passed things over to the Scottish Government or the Scottish intercollegiate guidelines network, and we have achieved absolutely nothing. The committee has to seriously consider carrying out an inquiry, because otherwise that will be five years of work for nothing.

Angus MacDonald SNP Falkirk East
link

A key issue that has come to light in the committee’s consideration of the petition relates to the evidence base for patient experience and clinical opinion. Do you consider that there are gaps in the existing research in that area and, if so, what gaps have you identified?

John Midgley
link

There is a rather stern answer to that. The alleged gaps in knowledge are in fact refusals to acknowledge that there is evidence that flies in the face of current actions. That is because the medical profession is by definition a conservative one and, having diagnosed and treated people in a particular way for 35 years, it does not take kindly to being told that it has been doing the wrong thing all that time.

It will take an enormous amount of pressure to bring the medical profession around to reading and understanding the papers—which I have to say are rather complicated—that show that what has been done over the past 35 years or so is suboptimal and has actually caused harm to patients. That is a very big thing for the medical profession to have to swallow but that is what, one day, it will have to do.

John Midgley
link

Yes.

Brian Whittle Con South Scotland
link

We understand from the Scottish Government’s latest submission that the chief scientist office has a remit to fund clinical research that is led by a Scotland-based clinician or scientist and which has the potential to improve the health and wellbeing of the people of Scotland. Have you approached any Scottish researchers to make a funding application to the chief scientist office to address any gaps in clinical evidence that you have identified?

John Midgley
link

My great disadvantage is that I am not medically qualified. That means that I can be easily ignored because that can be raised against me immediately. I do not have those connections and nobody from the health service in Scotland has approached me. Indeed, nobody in the world has approached me to talk in any forum about the situation. The invitations on my mantelpiece number zero and look to continue to be zero for the time being.

I believe that it is up to the authorities to debate the situation with me and for me and the appropriate people to have a discussion based on current evidence about how to proceed further.

Rona Mackay SNP Strathkelvin and Bearsden
link

I want to ask about the importance of the doctor-patient relationship in identifying suitable treatment and implementing patient-centred care. Are patients sufficiently supported when they do not agree with the treatment plan that is proposed by their general practitioner or endocrinologist? Do you have any recommendations for what steps NHS Scotland could take to support patients who find themselves in such circumstances?

John Midgley
link

Gosh, have we got a day? From what I read about people’s experiences, my belief is that, in general, GPs are woefully ignorant about how to treat patients who have thyroid dysfunction. GPs seem to have become used to what I call computer thinking—they look into a blue screen where advice is given to them and they simply follow that advice in a rigid and mechanical fashion.

That means that, as I said, the biochemical numbers, which are displayed on that screen from the pathology laboratory, seem to become paramount over the appearance of the person in front of the GP. In my opinion, that is the great error that is being made—the patient is now subordinate to the chemistry, which is not right. It cannot be right, because the chemistry is the guide and not the dictator. However, I cannot lay the fault at the door of the general practitioners, because they only behave in the way that they are instructed to behave.

09:45

I could go on for ages about this. The individual patient is an anecdote—they are in front of the GP and they have their unique parameters, which are within or without the normal range, depending on how they are. That is one thing. The normal ranges for health are obtained statistically. There is a tension between statistics and individuality. The individual is a place within those statistics, but to use the statistics backwards and say that an individual is within a range and is therefore okay, wherever they are, is a complete error.

I am saying that general practitioners are not given the proper method of discriminating the individual from the ranges that they are given within which to place that individual. The individuality is lost, and therefore misjudgments as to the success of the treatment are continually made.

I am afraid that that also applies to endocrinologists, who can be just as guilty of those errors as general practitioners. It is a matter of education, in my opinion.

Rona Mackay SNP Strathkelvin and Bearsden
link

Does that go back to clinical training?

John Midgley
link

Yes—clinical training has to change very much. There are an awful lot of misapprehensions about how to treat numbers and how to relate them to patient presentation.

Lorraine Cleaver
link

In the 21st century NHS, medicine is going forwards, but for this patient group we are going backwards. We used to have desiccated pig thyroid, which had everything in it, but we cannot get that now. We are actually going backwards.

I will read you part of a paragraph of a news report about a paper by an American scientist that was published in October last year, because I find it astonishing that this is happening in the 21st century. It states:

“Better medications are needed to treat hypothyroidism, Bianco believes. Until that day, he urges physicians to change how they talk about hypothyroidism with patients. ‘Doctors should be telling their patients, ‘I’m going to normalize your TSH, but you’re going to be at a higher risk for gaining weight, experiencing depression and fatigue. It is also more likely that your cholesterol will go up.’ That is what we should be telling our

patients.’”

Most of those patients will end up on statins and antidepressants. Doctors are saying to them, “I’m going to treat your TSH and reduce it until it is in a nice part of the range, but you are going to need statins, beta blockers, antidepressants and gosh knows how many other things.” That is outrageous in the 21st century.

They will do that rather than admit that what they are doing is wrong. They are medicating people with one drug that does not suit everyone, and they are medicating them to keep the TSH happy, rather than remove a person’s symptoms. It goes back to training and education. John Midgley was correct that it will take decades to unravel. The egos of the people who wrote the papers and decided on the protocols are not going to give up easily.

Elaine Smith Lab Central Scotland
link

I have a supplementary question on the GP issue.

First, I will put on the record, given what Lorraine Cleaver said, that Dr Anthony Toft, who is an eminent Scottish endocrinologist, commented on the BBC recently on the cost of T3; maybe we can come on to that. He was asked whether desiccated thyroid hormone was likely to be used instead, and he said:

“I suspect that in time that’s what will happen.”

To me, that is tragic. The people who are not getting it now cannot wait. They will end up on depression medicine, they might be suffering from fibromyalgia and so on. Regarding what Lorraine Cleaver just said, it is horrendous that it is only going to happen “in time”. Many women will suffer in the meantime and many of them will not be economically active as a result of it.

The committee has my own story. Loads of money was spent on testing me for conditions from Lyme disease to Addison’s disease and everything in between and putting me through a brain scan—which must have cost a fortune—heart monitoring and so on. All through that process, I said to every doctor, “I’ve got an underactive thyroid. It’s got something to do with that.” After spending two years and a fortune on this, I finally got to Dr Toft, who tested my T3 and found that I was not converting. I came back to life with a small pill, but it took two years. I was determined—how many women out there are not that determined?

From the paper that I have—I do not have the committee’s private papers—it is clear that there will be no SIGN guidance, so we are back to where we started. The paper says:

“a good practice guide for general practice may be a more useful document”,

and I want to ask Lorraine Cleaver about that. However, I note that the paper also says that the GPs noted that they are

“not in a position to comment on unlicensed medication.”

They are talking about desiccated thyroid hormone, which they used to prescribe 35 years ago—and it was unlicensed then, too. They are not in a position to comment on such medication, but they can prescribe it; indeed, some do, but they do so under the radar, because they see what happened to the late Dr Gordon Skinner, who kept getting hauled up before his professional body even though he had done no harm to his patients and was, in fact, doing them good.

I cannot understand how GPs can say that they are

“not in a position to comment on unlicensed medication”,

and I want John Midgley and Lorraine Cleaver to comment on that. How can GPs say that?

John Midgley
link

The behaviour of the opinion formers in thyroid medicine is verging on disgraceful. They refuse to allow desiccated thyroid to be licensed or used in this country for the very strange reason that it does not have the right content of thyroid hormones that are appropriate for treatment. That makes me scratch my head, because if you give patients only thyroxine, which is the normal treatment, that is about as unphysiological a thing as you can do. Indeed, it is far more unphysiological than giving natural desiccated thyroid—as long as the content of that product is regulated and controlled, which I believe it is according to the pharmacopoeias.

There is no real evidence on this and no reason not to be quite liberal in the choice of treatments that can be offered to patients according to their requirements and their responses to the treatments. I cannot see why there should just be narrow tramlines of suggestions and recommendations, given the fact that individual physiology is so widely defined and so widely corrected when wrong. I simply cannot see any logic in this narrow behaviour.

Angus MacDonald SNP Falkirk East
link

Like Elaine Smith, I cannot quite get my head around the issue of desiccated thyroid hormone, which we know has been available in the past and has worked. For clarification, I note that Lorraine Cleaver said a minute or two ago that it was unavailable, but I believe that we have had evidence that it is available on the internet from abroad. I presume that people are still buying it from there.

Lorraine Cleaver
link

I buy it from abroad, but I live with the fear that I will not be able to source it one day. It is licensed in America, but I am buying it via some company on the Pacific Ocean, which is ridiculous. The medical community removed my organ and told me, “We’ll put back what we took out”, but they are not doing it. They are leaving me and many thousands of other patients to buy it on the internet.

There is another problem with triiodothyronine—or T3—which I believe is being investigated by the Medicines and Healthcare products Regulatory Agency. The UK has one manufacturer of T3, and it seems to have a monopoly on price, which has gone from £54 for 28 tablets to £154. People’s medication is not supposed to be stopped because of cost, but that is what is happening. Elaine Smith has also been dealing with that.

I can see the position that the NHS is in. T3 costs £300-odd per month for some patients, but it costs one euro per pack in places such as Turkey. We are still in the EU—just about. Why can we not source cheaper T3 from there? Why is there only one manufacturer? Some patients have a tiny glimmer of hope that they can access T3 eventually, if their doctor prescribes it, but they are under constant threat of having it removed and that is happening.

Angus MacDonald SNP Falkirk East
link

Is the desiccated thyroid hormone available abroad at a reasonable price?

Lorraine Cleaver
link

The price has increased somewhat, but it works out at about £50 per month for me, which is still cheaper than the T3 that the NHS is getting stitched up over. I do not grumble about paying that, and that is how most patients feel. They do not have a problem about paying for it, but they have a fear about accessing it.

Johann Lamont Lab The Convener · Glasgow
link

I am conscious of the time. There are a lot of other questions that we could ask, but perhaps we could do so in writing. There is a very complicated set of issues involved, but I do not want to lose sight of the fact that we are right up against the clock. We could say that the question of licensing is not within the remit of the Parliament and is a question for elsewhere.

Do members have final questions that they want to ask?

Brian Whittle Con South Scotland
link

I have a comment. Through my work on this committee, I found out that a male friend of mine has this issue and was having real problems with thyroxine—or T4—until the consultant endocrinologist prescribed T3. My friend says that the combination of the two has made a huge impact on his life. I know that that is anecdotal evidence, but I spoke to his consultant, who told me that half of the consultants believe one point of view and the other half believe the other, which is really unhelpful. Proper clinical research has still not been achieved. I do not know what the answer is, but somehow or other that circle has to be closed.

Johann Lamont Lab The Convener · Glasgow
link

We should certainly flag up the research issue to the Scottish Government. It feels as though there is an awful lot more to be established around licensing, which is not within the committee’s power. However, we are also interested in people’s concern about the way in which they have been treated.

Maurice Corry Con West Scotland
link

Does Dr Midgley think that clinicians have clear guidance on when to use different types of diagnostic tests?

John Midgley
link

No; I do not think that they are given guidance at all, at GP level. The dogma is always, “Take the thyroxine and normalise your TSH. Thank you, madam or sir. Go away; you are properly treated.” That is the end of it. If a patient feels ill, that is put down to something else, such as their being depressed or having a cold, but not to their having a thyroid problem. I am afraid that the ignorance on that is quite astounding.

One thing that I want to run over quickly is that the instruments that are used to measure the thyroid hormones from different manufacturers do not give the same answers. Therefore there is extra confusion, in which the normal range from one manufacturer can be up to 50 per cent different from the normal range from another. The confusion can be astounding and, in the case of T3, it is awful. The standard of measurement is as bad as the standard of diagnosis. How we get on, I do not know.

Elaine Smith Lab Central Scotland
link

Licensing is a slight red herring, because GPs can prescribe desiccated thyroid hormone if they want to. When T3 ran out a few years ago, when the committee was dealing with the issue, GPs could not get it and were then told to get it from abroad, from wherever they could. Licensing aside, GPs could still get it, but they are frightened to prescribe it because they are being hauled in front of their professional bodies for doing so.

Johann Lamont Lab The Convener · Glasgow
link

As I said, there may be points that we want to pursue at a later stage, but I am conscious of time this morning. I thank the witnesses for their attendance.

We want to produce a revised draft report. We should reflect on the evidence that we have heard today and any follow-up questions that we may have before we complete that report. Is there anything else that members think we should do?

10:00

Rona Mackay SNP Strathkelvin and Bearsden
link

This is such a big issue and it is a shame that we have had to round off our discussion. I do not expect the witnesses to answer this, as we have run out of time, but I would be interested to know what their priority would be to improve the situation. I know that there is a list of things—perhaps they could be explored in a letter.

Lorraine Cleaver
link

We should roll back everything—all the problems that we have about the tests and the medicine being inadequate—and go right back to the source of the guidance that is handed out to GPs, which is why we are in this position. The guidelines were written based on consensus, and that consensus medicine is not science. We should go back to the source and ask why it is acceptable for guidance on such a common illness to be based on consensus rather than on good-quality evidence. We are firefighting and the problem is way back at the source.

Brian Whittle Con South Scotland
link

I am reading that the guidance is from the National Institute for Health and Care Excellence, but surely the Scottish Medical Council has jurisdiction here, not NICE.

Johann Lamont Lab The Convener · Glasgow
link

That can be clarified. I think that we are dealing with SIGN guidance, but we can get that clarified.

Elaine Smith Lab Central Scotland
link

Given that all this time has passed and we are back at stage 1 on the guidance, and given that, as it says in the committee’s papers, GPs will not take on board good practice guidance, is there no possibility that the committee could hold an inquiry into the issue? All that happened in the beginning was a round table, which provided more questions than answers, and the petitioner has been before the committee a few times. However, this is a new committee and only one member has experience of the stories that were put together in a hurry. Is there any time in your timetable for an inquiry?

Johann Lamont Lab The Convener · Glasgow
link

Obviously we have reflected on our business programme for next year, as all committees do. I am keen to finish our revised draft report, and we can draw conclusions from that. Although not all committee members were on the predecessor committee, we have read and reflected on the evidence. We have to balance the interests of the petition with all the other pressures that we are under. You can rest assured that we will at least be looking at it.

I thank the witnesses again for their attendance.

10:02 Meeting suspended.

10:04 On resuming—

  1. 08:45 New Petitions Petitions · 9
  2. 08:45 New Petitions Petitions · 4
  3. 08:45 New Petitions Petitions · 11
  4. 08:45 Continued Petitions Petitions · 12
  5. 08:45 Continued Petitions Petitions · 7
  6. 09:15 Continued Petitions Petitions · 12
  7. 09:15 Continued Petitions Petitions · 12
  8. 09:15 Continued Petitions Petitions · 10
  9. 09:15 Continued Petitions Petitions · 38
  10. 10:00 New Petition Petitions · 35
  11. 10:15 Continued Petition Petitions · 225

The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.